News

Eli Lilly is recruiting patients for its Phase 2 clinical trial evaluating LY3154207 as a potential treatment for Parkinson’s disease dementia (PDD). Parkinson’s disease destroys the nerve cells that make dopamine, a key player in nerve cell communication and involved in movement control, cognition, memory, learning, attention, and sleep. Parkinson’s…

Charles River Laboratories International and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) extended their collaboration to accelerate the discovery of Parkinson’s disease therapies. The extension covers grants from MJFF to characterize two animal models of Parkinson’s — one where mice do not express alpha-synuclein (knockout), and another…

New methods to measure brain activity in dancers can be applied to develop new forms of treatment, such as dance-movement therapy, for movement-related disorders including Parkinson’s disease, according to a Finnish PhD candidate. Her research project, “Dance on Cortex – ERPs and Phase Synchrony in Dancers and Musicians during a…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Verily Life Sciences are collaborating to collect data on movement, physiological, and environmental measures in Parkinson’s patients for the MJFF-led Parkinson’s Progression Markers Initiative (PPMI). More than 800 PPMI participants will be outfitted with Verily’s investigational Study Watch, a multi-sensor…

Rate hypothesis, a theory that Parkinson’s results from an imbalance in brain signals telling the body to start and stop moving,  may involve  “start” and “stop” signals that are more complex and intricate than initially thought, Stanford researchers report. And, the researchers suggest, the loss of that complexity and structure might factor in…

Insightec has treated the first patient in a pivotal study of its non-invasive ultrasound therapy, ExAblate Neuro, for patients with advanced Parkinson’s who have not responded to medication. The device uses focused ultrasound and magnetic resonance imaging (MRI) to destroy a target deep in the brain — the Vim…

Worldwide Clinical Trials and Datavant have teamed up to improve research and clinical trial design for neurodegenerative diseases like Parkinson’s disease. The collaboration will combine Worldwide’s expertise in neurodegenerative diseases and clinical trial regimens with Datavant’s experience in organizing and structuring healthcare data. It intends to study…

Improved understanding of Parkinson’s disease psychosis (PDP) and a unified approach for its clinical evaluation are key for developing new therapeutics, a review study suggests. The research, “Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis,” was published in the journal Current Psychiatry Reports. PDP has been…

e-Therapeutics recently entered a collaboration agreement with C4X Discovery to identify new intervention strategies for the treatment of Parkinson’s disease. The collaboration is based on leveraging e-Therapeutics’ Network-Driven Drug Discovery (NDD) platform for drug discovery with C4X Discoveries’ Taxonomy3 technology to identify new cellular mechanisms that are important…

Dopamine-releasing neurons are important players in the formation of new, long-term memories,  research shows. These findings may help develop new therapies for memory disorders. The study “Novelty-Sensitive Dopaminergic Neurons in the Human Substantia Nigra Predict Success of Declarative Memory Formation” was published in the journal Current Biology.